Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.32 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

Earnings

Adaptimmune Reports Third Quarter 2016 Financial ResultsNovember 10, 2016 6:30 AM Form 8-K Adaptimmune Therapeutics For: Nov 09November 9, 2016 4:24 PM Adaptimmune Therapeutics (ADAP) will resume trading at 4:35pm ETNovember 9, 2016 4:13 PM Adaptimmune Therapeutics (ADAP) Announces Lift of FDA Partial Clinical Hold on NY‑ESO SPEAR in MRCLSNovember 9, 2016 4:06 PM Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)November 9, 2016 4:05 PM Adaptimmune Therapeutics (ADAP), Novavax (NVAX) trading halted with news pending.November 9, 2016 4:01 PM